Soleno Therapeutics Soars as Neurocrine Unveils $2.9B All-Cash Buyout at $53 a Share

Neurocrine Biosciences executives outlined plans to get Soleno Therapeutics (NASDAQ:SLNO) successful an all-cash transaction that they said would adhd a recently launched rare-disease medicine and accelerate Neurocrine’s gross maturation and portfolio diversification strategy.

On a league call, Neurocrine CEO Kyle Gano said the institution entered into a definitive statement nether which Neurocrine, done a subsidiary, volition commence a currency tender connection for each outstanding shares of Soleno astatine $53 per share, for a full endeavor worth of astir $2.9 billion. Gano said the transaction is not taxable to a financing condition and volition beryllium funded with currency connected hand, with Neurocrine readying “to optimize our superior operation by taking connected a humble level of pre-payable debt.”

→ 3 Utility Stocks With Strong Dividends and Room to Run Higher

Gano characterized Soleno arsenic “an exceptional strategical and fiscal fit,” arguing the acquisition reinforces Neurocrine’s absorption connected “therapies that are transformative for patients.” He said the summation of Soleno’s merchandise would “immediately increase” Neurocrine’s top-line gross maturation and enactment sustained maturation and worth creation.

Samir Siddhanti, Neurocrine’s vice president of strategy and concern development, said Soleno’s merchandise VYKAT XR was approved by the FDA successful March 2025 and launched successful the U.S. successful the second quarter. Siddhanti said the motorboat generated $190 cardinal successful 2025 revenue for Soleno, including $92 cardinal successful the 4th quarter, which helium said reflected beardown doc adoption and the product’s interaction connected patients and caregivers.

→ Why Meta's "Bellwether" Legal Loss Could Open up a Can of Worms

Neurocrine executives repeatedly described VYKAT XR arsenic a first-in-class attraction for hyperphagia associated with Prader-Willi syndrome (PWS). Siddhanti said PWS is simply a uncommon familial neurodevelopmental upset affecting astir 10,000 radical successful the United States and that its defining diagnostic is hyperphagia, which helium described arsenic “a chronic and life-threatening condition” involving persistent hunger, compulsive food-seeking behavior, and important quality-of-life impacts.